Media & Investors

Media and Investor Information

Financials

According to the current position, the second half-year will be considerably better compared with the reporting period. We expect a growth in turnover of approximately 18 % versus the forecast 15 %. On this basis, we will raise the outlook for the operating result to approximately CHF 60 million.

More facts & figures

Coming events

DateEvent
Place
24 May 2018 Media conference and analysts’ presentation of the
annual figures 2017/18
Burgdorf
27 June 2018 General Meeting of Shareholders Burgdorf

Investor agenda

Latest News

Ypsomed grows during first half-year and raises its forecast for the year

Burgdorf, 09.11.2017, 7.00 a.m. – During the first six months of the business year 2017/18, Ypsomed generated a consolidated total turnover of CHF 213.4 million. The growth corresponds to an increase in turnover of 15.1% (previous year: CHF 185.4 million). The net profit for the reporting period amounts to CHF 23.4 million (previous year CHF 22.4 million). The operating result amounts to CHF 26.9 million with an EBIT margin of 12.9 %. Ypsomed expects a growth in turnover of approximately 18% versus the presently forecast 15% and increases the forecast to an operating result of around CHF 60 million for the business year 2017/18.

Ypsomed supplies Bigfoot Biomedical with infusion sets

Burgdorf, 24.10.2017, 7.00 a.m. – Ypsomed and the US Bigfoot Biomedical company today announced their agreement for a partnership. Ypsomed will supply Bigfoot Biomedical with a modified, patented version of the Orbit infusion set. This will be used by Bigfoot in their clinical study on automated insulin therapy in people with diabetes.

Ypsomed opens up new markets

Burgdorf, 10.10.2017, 7.00 am – Following the successful launch of its own insulin pump, the mylife YpsoPump, Ypsomed pursues its continued growth and invests in establishing new subsidiaries throughout Europe. At the same time, the mylife YpsoPump is being launched in further European countries.

Go-ahead for Ypsomed’s new production facility in Schwerin

Burgdorf, 27th September 2017, 7.00 a.m. – On 26th September 2017, groundbreaking took place for Ypsomed’s new production facility in the Industrial Park of Schwerin, Germany. Ypsomed is to invest over EUR 100 million in the new production site. Production will commence during the first half of 2019. Ypsomed plans to create roughly 150 jobs in the region over the next five years. 

Ypsomed to separate from Insulet and extend its portfolio with an own patch pump in the mid-term

Burgdorf, 21 July 2017, 7 a.m. – Ypsomed has been the exclusive distributor for the mylife OmniPod® patch pump outside the USA since 2010. During this period, Ypsomed established therapy with the innovative insulin pump in Europe, gaining market shares of up to 20% in part. The distribution agreement with Insulet Corp. will end as per 30 June 2018. The parties could not agree on extending the contract as the price demanded by Insulet Corp. would have made continued economic viability impossible. Ypsomed is well set for the future and will introduce its own tubeless mylife YpsoPod® insulin pump in the mid-term.